Search / Trial NCT00002055

A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP

Launched by FISONS · Aug 30, 2001

Trial Information

Current as of January 03, 2025

Completed

Keywords

Aids Related Opportunistic Infections Pneumonia, Pneumocystis Carinii Pentamidine Dose Response Relationship, Drug Aerosols Acquired Immunodeficiency Syndrome

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Zidovudine (AZT).
  • Patients must have:
  • AIDS.
  • Recovered from their most recent episode of Pneumocystis carinii pneumonia (PCP). Patients must be at least 2 weeks status post therapy for acute PCP.
  • Adequate pulmonary function (vital capacity = or \> 65 percent of predicted; forced expiratory volume, 1 s = or \> 55 percent of total FEV; and corrected pulmonary diffusion capacity \> 50 percent of predicted).
  • Patients must be free of acute medical problems.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following are excluded:
  • AIDS-defining opportunistic infection prior to entry such as toxoplasmosis and cryptococcosis.
  • Pulmonary Kaposi's sarcoma.
  • Asthma poorly controlled by medication.
  • Receiving active therapy for tuberculosis.
  • Concurrent Medication:
  • Excluded:
  • Active therapy for tuberculosis.
  • Patients with the following are excluded:
  • Requiring ongoing active therapy for an opportunistic infection at time of study entry.
  • AIDS-defining opportunistic infection prior to study entry such as toxoplasmosis and cryptococcosis.
  • Pulmonary Kaposi's sarcoma.
  • Unwilling to sign informed consent.
  • Asthma poorly controlled by medication.
  • Unwilling to cooperate with study procedures.
  • Receiving active therapy for tuberculosis.
  • Prior Medication:
  • Excluded within 30 days of study entry:
  • Antiretrovirals (other than zidovudine (AZT)).
  • Immunomodulating agents.
  • Corticosteroids.
  • Prior Treatment:
  • Excluded within 7 days of study entry:
  • Transfusion.
  • Patient cannot be transfusion dependent (requiring blood transfusion more than once per month).
  • Active substance abuse.

About Fisons

Fisons is a distinguished pharmaceutical company dedicated to advancing healthcare through innovative research and development. With a strong focus on providing effective therapeutic solutions, Fisons specializes in a diverse range of medical fields, including respiratory, oncology, and infectious diseases. Committed to rigorous clinical trials and ethical standards, the company aims to bring safe and effective medications to market, improving patient outcomes and quality of life. Fisons leverages its extensive expertise and collaborative partnerships to drive scientific discovery and ensure compliance with regulatory requirements, positioning itself as a leader in the pharmaceutical industry.

Locations

Chicago, Illinois, United States

Boston, Massachusetts, United States

Washington, District Of Columbia, United States

Washington, District Of Columbia, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials